CoChat
Sign Up
Cited by 719Economic and Financial Impacts of CancerHealth Systems, Economic Evaluations, Quality of LifeAdvances in Oncology and Radiotherapy

The DOI matches its Crossref record; 273 of the 279 references it cites were found in a registry or an index.

Delivering affordable cancer care in high-income countries

Sullivan, Richard, Peppercorn, Jeffrey, Sikora, Karol, Zalcberg, John, Meropol, Neal J, Amir, Eitan, Khayat, David, Boyle, Peter, Autier, Philippe, Tannock, Ian F, Fojo, Tito, Siderov, Jim, Williamson, Steve, Camporesi, Silvia, McVie, J Gordon, Purushotham, Arnie D, Naredi, Peter, Eggermont, Alexander, Brennan, Murray F, Steinberg, Michael L, De Ridder, Mark, McCloskey, Susan A, Verellen, Dirk, Roberts, Terence, Storme, Guy, Hicks, Rodney J, Ell, Peter J, Hirsch, Bradford R, Carbone, David P, Schulman, Kevin A, Catchpole, Paul, Taylor, David, Geissler, Jan, Brinker, Nancy G, Meltzer, David, Kerr, David, Aapro, Matti·2011·The Lancet Oncology
DOI 10.1016/s1470-2045(11)70141-3
Open this paper in CoChat — free account

Abstract

The burden of cancer is growing, and the disease is becoming a major economic expenditure for all developed countries. In 2008, the worldwide cost of cancer due to premature death and disability (not including direct medical costs) was estimated to be US$895 billion. This is not simply due to an increase in absolute numbers, but also the rate of increase of expenditure on cancer. What are the drivers and solutions to the so-called cancer-cost curve in developed countries? How are we going to afford to deliver high quality and equitable care? Here, expert opinion from health-care professionals, policy makers, and cancer survivors has been gathered to address the barriers and solutions to delivering affordable cancer care. Although many of the drivers and themes are specific to a particular field-eg, the huge development costs for cancer medicines-there is strong concordance running through each contribution. Several drivers of cost, such as over-use, rapid expansion, and shortening life cycles of cancer technologies (such as medicines and imaging modalities), and the lack of suitable clinical research and integrated health economic studies, have converged with more defensive medical practice, a less informed regulatory system, a lack of evidence-based sociopolitical debate, and a declining degree of fairness for all patients with cancer. Urgent solutions range from re-engineering of the macroeconomic basis of cancer costs (eg, value-based approaches to bend the cost curve and allow cost-saving technologies), greater education of policy makers, and an informed and transparent regulatory system. A radical shift in cancer policy is also required. Political toleration of unfairness in access to affordable cancer treatment is unacceptable. The cancer profession and industry should take responsibility and not accept a substandard evidence base and an ethos of very small benefit at whatever cost; rather, we need delivery of fair prices and real value from new technologies.

Overview

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(11)70141-3

Cites

273 of 273 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 279 references

Research works printed but not linked: 2

  1. Jönsson, 2007, The burden and cost of cancer, Ann Oncol, 18, 8
  2. Stark, 2009, The burden of cancer in Europe and the availability of cancer drugs, EJHP Practice, 15, 20

Cited by

Sorted by citations

See all 719

Related

Metadata

Authors
Sullivan, R., Peppercorn, J., Sikora, K., Zalcberg, J., Meropol, N. J., Amir, E., Khayat, D., Boyle, P., Autier, P., Tannock, I. F., Fojo, T., Siderov, J., Williamson, S., Camporesi, S., McVie, J. G., Purushotham, A. D., Naredi, P., Eggermont, A., Brennan, M. F., Steinberg, M. L., De Ridder, M., McCloskey, S. A., Verellen, D., Roberts, T., Storme, G., Hicks, R. J., Ell, P. J., Hirsch, B. R., Carbone, D. P., Schulman, K. A., Catchpole, P., Taylor, D., Geissler, J., Brinker, N. G., Meltzer, D., Kerr, D., & Aapro, M.
Affiliations
  • Guy's Hospital (GB)
  • Duke Medical Center (US)
  • The University of Melbourne (AU)
  • University Hospitals Seidman Cancer Center (US)
  • University of Toronto (CA)
  • Pitié-Salpêtrière Hospital (FR)
  • International Prevention Research Institute (FR)
  • National Cancer Institute (US)
  • Austin Hospital (AU)
  • Northumbria Healthcare NHS Foundation Trust (GB)
  • King's College London (GB)
  • European Institute of Oncology (IT)
  • Umeå University (SE)
  • Institut Gustave Roussy (FR)
  • Memorial Sloan Kettering Cancer Center (US)
  • University of California, Los Angeles (US)
  • Vrije Universiteit Brussel (BE)
  • Peter MacCallum Cancer Centre (AU)
  • University College London (GB)
  • Duke University (US)
  • Vanderbilt University Medical Center (US)
  • Association of the British Pharmaceutical Industry (GB)
  • University of London (GB)
  • Susan G. Komen Breast Cancer Foundation (US)
  • University of Chicago (US)
  • University of Oxford (GB)
  • Clinique de Genolier (CH)
Corresponding author
Sullivan, Richard
ORCID
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2011-09
Volume
12
Issue
10
Pages
933-980
ISSN
1470-2045 (ISSN-L)
DOI
10.1016/s1470-2045(11)70141-3
OpenAlex
W2111285159
Cited by
718
References
279
Citations by year
2026: 21 · 2025: 24 · 2024: 34 · 2023: 16 · 2022: 33 · 2021: 43 · 2020: 40 · 2019: 32 · 2018: 60 · 2017: 45 · 2016: 56 · 2015: 67 · 2014: 75 · 2013: 81 · 2012: 76
FWCI
199.54
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • The Lancet Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • Strathprints: The University of Strathclyde institutional repository (University of Strathclyde) (acceptedVersion)
  • UCL Discovery (University College London) (submittedVersion)
  • Research Portal (King's College London) (submittedVersion)
  • VUBIR (Vrije Universiteit Brussel) (submittedVersion)
Funders
  • Conquer Cancer Foundation
  • King's College Hospital NHS Foundation Trust
  • National Institute for Health and Care Research
  • Department of Health and Social Care
  • King's College London
Topics
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Economic and Financial Impacts of Cancer
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Advances in Oncology and Radiotherapy
Keywords
cancer costs, high-income countries, value-based pricing, access to cancer treatment, health equity, regulatory regimes, health policy, overuse of health care
MeSH terms
Australia, Cost-Benefit Analysis, Europe, Health Expenditures, Health Policy, Health Services Accessibility, Health Services Misuse, Health Services Research, Humans, Insurance, Health, Neoplasms, Socioeconomic Factors, United States, Cost Savings, Health Care Costs, Health Care Reform, Models, Economic, Delivery of Health Care, Integrated, Healthcare Disparities

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review